U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens (Q37100603)
Jump to navigation
Jump to search
scientific article published on March 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens |
scientific article published on March 2008 |
Statements
1 reference
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens (English)
1 reference
Ruthann M Giusti
1 reference
Kaushikkumar Shastri
1 reference
Anne M Pilaro
1 reference
Chana Fuchs
1 reference
Ruth Cordoba-Rodriguez
1 reference
Kallappa Koti
1 reference
Mark Rothmann
1 reference
Angela Yuxin Men
1 reference
Hong Zhao
1 reference
Monica Hughes
1 reference
Patricia Keegan
1 reference
Karen D Weiss
1 reference
Richard Pazdur
1 reference
1 March 2008
1 reference
1 reference
14
1 reference
5
1 reference
1296-1302
1 reference
Identifiers
1 reference
1 reference